Literature DB >> 22855781

Investigating the impact of hepatitis B virus surface gene polymorphism on antigenicity using ex vivo phenotyping.

Samreen Ijaz1, Renata Szypulska1, Nick Andrews2, Richard S Tedder3,4,1.   

Abstract

The hepatitis B virus (HBV) surface antigen (HBsAg) is a complex protein, and understanding accurately the impact of amino acid changes on the antigenicity of the immunodominant a determinant must take this complexity into consideration. Epitope mapping with four mAbs was used to phenotype HBsAg directly from patients' sera to investigate the effect of mutations in their native genetic backbone. The expected mAb reactivity was established initially for samples harbouring 'wild-type' HBsAg sequences across genotypes A-E. The alteration of HBsAg antigenicity, defined by mAb epitope loss, was demonstrated in a number of samples with sequence-inferred amino acid changes. Individual mutations within the mapped epitopes to which the mAbs were directed usually affected their binding. However, the loss of more than one epitope was observed as the number of mutations within a sequence increased. Conversely, not all mutations occurring in the a determinant altered the HBsAg conformation. The genotype backbone, the specific amino acid substitution and amino acid changes occurring outside the major antigenic region appeared to be important in determining expression of the predicted epitope loss. These data clearly demonstrate that sequence-based methods alone may not accurately define HBsAg phenotype. This phenotyping methodology allows for the rapid and accurate identification of antigenically altered viruses and will greatly enhance current HBV surveillance, research and diagnostic activities. The data generated can be used to inform on public health issues relating to prevalence, transmission and impact of HBsAg mutants in HBV-infected populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855781     DOI: 10.1099/vir.0.044305-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations.

Authors:  Qiao Wang; Eleftherios Michailidis; Yingpu Yu; Zijun Wang; Arlene M Hurley; Deena A Oren; Christian T Mayer; Anna Gazumyan; Zhenmi Liu; Yunjiao Zhou; Till Schoofs; Kai-Hui Yao; Jan P Nieke; Jianbo Wu; Qingling Jiang; Chenhui Zou; Mohanmmad Kabbani; Corrine Quirk; Thiago Oliveira; Kalsang Chhosphel; Qianqian Zhang; William M Schneider; Cyprien Jahan; Tianlei Ying; Jill Horowitz; Marina Caskey; Mila Jankovic; Davide F Robbiani; Yumei Wen; Ype P de Jong; Charles M Rice; Michel C Nussenzweig
Journal:  Cell Host Microbe       Date:  2020-06-05       Impact factor: 21.023

Review 2.  Molecular mechanisms underlying HBsAg negativity in occult HBV infection.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-24       Impact factor: 3.267

Review 3.  Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.

Authors:  Timothy M Block; Stephen Locarnini; Brian J McMahon; Barbara Rehermann; Marion G Peters
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

4.  The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa.

Authors:  M I Andersson; T G Maponga; S Ijaz; J Barnes; G B Theron; S A Meredith; W Preiser; R S Tedder
Journal:  Vaccine       Date:  2013-08-21       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.